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Gremlin, A potential Urinary 
Biomarker of Anca-Associated 
Crescentic Glomerulonephritis
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Constanza saka1, Jesús egido2, Marta Ruiz-ortega2 & sergio Mezzano1
Gremlin renal overexpression has been reported in diabetic nephropathy, pauci-immune crescentic 
glomerulonephritis and chronic allograft nephropathy and has been implicated in the pathophysiology 
of the progression of renal damage. However, it is unknown whether urinary Gremlin can be associated 
with renal functional status, renal biopsy findings and outcome. To examine these associations we 
studied 20 patients with ANCA+ renal vasculitis and very high urinary Gremlin (354 ± 76 ug/gCr), 86 
patients with other glomerular diseases and moderately elevated urinary Gremlin (83 ± 14 ug/gCr) and 
11 healthy controls (urinary Gremlin 11.3 ± 2.4 ug/gCr). Urinary Gremlin was significantly correlated 
with renal expression of Gremlin (r = 0.64, p = 0.013) observed in cellular glomerular crescents, tubular 
epithelial cells and interstitial inflammatory cells. Moreover, urinary Gremlin levels were correlated with 
the number of glomerular crescents (r = 0.53; p < 0.001), renal CD68 positive cells (r = 0.71; p < 0.005), 
tubulointerstitial fibrosis (r = 0.50; p < 0.05), and serum creatinine levels (r = 0.60; p < 0.001). 
Interestingly, Gremlin expression was colocalized with CD68, CD163 (monocyte/macrophage markers) 
and CCL18 positive cells. ROC curve analysis showed that the cutoff value of urinary Gremlin in 
glomerular diseases as 43 ug/gCr with 72% of sensitivity and 100% of specificity [AUC: 0.96 (CI 95% 
0.92–0.99] (p < 0.001). For ANCA+ renal vasculitis the value of urinary Gremlin of 241 ug/gCr had 55% 
of sensitivity and 100% of specificity [AUC: 0.81 (CI 95% 0.68–0.94) (p < 0.001]. Based on these results 
we propose that urinary Gremlin represents a non-invasive biomarker in ANCA+ renal vasculitis, and 
suggest a role of Gremlin in the formation of crescents.
Gremlin was identified as one of developmental genes, re-expressed during renal damage that could play a role in 
the progression of diabetic nephropathy and other chronic renal diseases1.
Gremlin belongs to a family of bone morphogenetic proteins (BMPs) antagonists2–4 that have a well-recognized 
role in organogenesis and fibrotic related disorders5–7 Gremlin is induced by TGF-β in renal cells2, and it is a 
downstream mediator of TGF-β, activating the Smad pathway and inducing epithelial-mesenchymal transition8. 
Moreover, in a BMP-independent manner, Gremlin could contribute to renal inflammation via vascular endothe-
lial growth factor receptor 2 pathway9.
Gremlin knockout mice die of renal aplasia, lung defects and limb malformations7,10–14, and we have recently 
shown that Gremlin tubular overexpression aggravates folic acid-induced and streptozotocin-induced renal 
damage15,16.
In human diabetic nephropathy, Gremlin is most prominently expressed in podocytes and areas of tubu-
lointerstitial fibrosis, colocalized with TGF-β expression and correlated with tubulointerstitial score damage17,18. 
Gremlin has also been observed in various nephropathies, notably in pauci-immune crescentic vasculitis where 
strong expression of Gremlin mRNA and protein were observed at glomerular crescents, and in tubular and 
infiltrating interstitial cells19. However, it is not known if Gremlin is present in the urine during kidney injury and 
whether it could be a novel biomarker with diagnostic or prognostic value in glomerular diseases. The present 
study was done to answer these questions.
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Material and Methods
patients studied. We studied 106 consecutive patients with a glomerular disease, admitted for a diagnostic 
renal biopsy. 20 of them with ANCA-associated pauci-immune glomerulonephritis (ANCA CGN), 26 Systemic 
Lupus Erythematosus (SLE), 18 Membranous Nephropathy (MGN), 23 patients with IgA nephropathy (IgAN), 
and 19 Focal Segmental Glomerulosclerosis (FSGS).
Clinical and demographic data of these patients are presented in Tables 1 and 2, and Fig. 1.
All the patients with ANCA+ crescentic glomerular disease were developing a rapidly progressive renal failure 
(Fig. 1), with history of microhematuria, dysmorphic red blood cells and/or red cell casts and with 23 to 100% of 
glomerular crescents. We defined as a non-ANCA crescentic glomerulonephritis (non-ANCA CGN), a subgroup 
of 20 patients with SLE or IgA nephropathy, with >25% of glomerular crescents.
Human renal biopsies. Kidney samples were obtained by percutaneous renal biopsy performed at the 
Division of Nephrology, Austral University, Valdivia, Chile. The samples were studied after informing and 
obtaining the patient written consent and the approval by local hospital ethics committee (Comité de Ética de 
Investigación, Servicio de Salud Valdivia, Ministerio de Salud, Chile ORD-No. 120/2016). The study was in 
adherence with the Declaration of Helsinki. Light microscopy, immunofluorescence (IF) and electron microscopy 
studies were performed using routine methods for diagnostic use.
Urine samples. Urine samples from patients were collected the same day and prior to renal biopsy. Samples 
were immediately centrifuged for 15 minutes at 3000 rpm and the supernatants stored at −80 °C. Urinary Gremlin 
was determined no later than 3 month after collection avoiding repeated freeze-thaw cycles. Gremlin was deter-
mined using an enzyme-linked immunosorbent assay with biotin-conjugated antibody specific to GREM1, 
followed by avidin conjugated to horseradish peroxidase. The sensitivity or lower limit of detection is less than 50 pg/ml 
and the intraassay and inter-assay coefficient of variability (CV) are <10% and <12%, respectively (Uscn Life 
ANCA 
CGN 
Patient
Age 
(years)
Gender 
(F/M)
Urinary 
Gremlin 
(ug/gCr)
Serum 
Creatinine 
(mg/dl)
Crescent 
(%)
Masson (% 
staining 
area)
ANCA URINALYSIS
IFI
ELISA
(U/ml)
Prot  
(mg/dl)
RBC (cells/
field) Casts
1 41 F 1408 4.1 46 4 c 5 PR3 75 0–2 (—)
2 81 F 36 1.9 29 2.7 p >100 MPO 75 10–20 (—)
3 83 F 665 4.6 67 1.8 p >100 MPO 150 20–30 hyaline granular
4 63 F 333 6.1 86 1.6 p 20 MPO 500 5–10 hyaline
5 68 F 78 1.7 38 2.0 p 9 MPO 500 5–10 hyaline
6 72 F 413 10.6 58 10.9 p 93 MPO 150 80–90 granular
7 67 M 892 7.8 75 2.1 p >100 MPO 300 20–50 hyaline
8 33 F 644 5.8 23 8.7 p 73 MPO 150 20–50 RBCs granular
9 60 M 417 4.3 30 8.4 p 9 MPO 300 20–30 (—)
10 56 F 362 6.8 40 5.1 p >100 MPO 300 10–20 RBCs
11 64 F 292 4.3 63 5.5 p 10 MPO 500 0–2 hyaline
12 59 M 490 3.5 50 10.8 p nt 150 60–70 (—)
13 60 F 75 1.3 36 7.1 p 84 MPO 150 10–20 hyaline granular
14 67 M 132 5.8 100 0.3 p 76 MPO 75 80–90 (—)
15 56 M 59 0.8 40 2.8 p 18 MPO 75 80–90 hyaline granular
16 21 F 159 0.9 40 15.8 p nt 75 20–50 hyaline
17 69 F 96 7.7 50 2.8 p 9 MPO 150 20–50 granular
18 60 M 168 6.9 50 6.8 p 9 MPO 100 30–40 (—)
19 29 F 256 2.1 100 4.0 p 38 MPO 75 20–50 hyaline granular
20 61 M 100 7.9 71 5.8 c 7.4 PR3 30 20–30 (—)
Table 1. Clinical and demographic data of patients with ANCA + CGN. nt:non tested, RBC:red blood cells, 
MOP:Mieloperoxidase, PR3:proteinase 3.
n
Gender 
(M/F) Age x (years)
Serum Creatinine 
(mg/dl)
Proteinuria 
(mg/dl)
ANCA CGN 20 7/13 58.5 ± 3.6 4,6 ± 0.6 194.0 ± 34.3
SLE 26 5/21 34.3 ± 2.2 2.0 ± 0.4 342.8 ± 68.5
MGN 19 7/12 49.6 ± 3.3 0.83 ± 0.1 442.6 ± 48.5
IgAN 23 12/11 36.4 ± 3.1 1.2 ± 0.1 102.2 ± 52.5
FGS 18 8/10 45.1 ± 3.9 1.4 ± 0.2 298.9 ± 44.2
NORMAL 16 4/12 36.8 ± 3.2 nd 0
Table 2. Clinical and demographic data of patients studied.
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Science Inc., Wuhan, China). Urinary and serum creatinine were measured with Creatinine Liquicolor Kit 
(Human Gesellschaftfür Biochemica und DiagnostikambH, Wiesbaden, Germany) and Cobas CREJ2 (Roche 
Diagnostics Limited, Mannheim, Germany), respectively.
Immunohistochemistry (IHC). Paraffin-embedded renal sections were used for detection of Gremlin, 
CD163, CD68 and CCL18. The following primary antibodies were employed: rabbit polyclonal anti-Gremlin 
(dilution 1:300, ABGENT, AP6133a, San Diego CA, USA); rabbit polyclonal anti-CCL18 (dilution 1:100, 
Sigma-Aldrich, Saint Louis, MO USA); mouse monoclonal anti-CD163, monocyte/macrophage marker (dilution 
1:500, CELL MARQUE, Rocklin CA, USA) and mouse monoclonal anti-CD68 (Kp-1) monocyte/macrophage 
marker (dilution 1:500, CELL MARQUE). IHC was performed following heat-induced epitope retrieval (HIER) 
[microwaving for 10 min in citrate buffer for Gremlin and CCL18 and Trilogy (CELL MARQUE) for CD163 
and CD68]. After blockage endogenous peroxidase activity and non-specific-background with Power Block 
(Biogenex, Fremont CA, USA), the slides were incubated with primary antibody overnight at 4 °C and detected 
with Immpress Reagent (Vector, Burlingame CA, USA). The reaction was developed with DAB (SK 4105, Vector) 
and counterstained with hematoxylin.
Image analysis and quantification of the IHC signals were performed using the KS300 imaging system, version 
3.0 (Zeiss). For each sample, the mean staining area was obtained by an analysis of 20 fields (x20). The staining 
score is expressed as square millimeters per density.
In situ hybridization (ISH). It was performed as previously describedfor Gremlin18, using the following 
antisense Gremlin probes: 5′-TGAAAGGAACCTTCCTCCTTCC3′, 5′-ATGGGAGAGCACTGGATCAAAA-3′ 
and 5′-CAGGCACTGACTCAGGAAGACA-3. The specificity of the reaction was confirmed by RNAse treat-
ment, using a sense probe, or without probe.
statistical analysis. Statistical analysis was conducted using SPSS Statistics version 20 and Graphpad 
Prism 7. Numerical variables are listed as mean and standard deviation or median and interquartile range. 
Mann-Whitney and Kruskal-Wallis tests were used to compare urinary Gremlin between different renal patholo-
gies and healthy controls. Wilcoxon test to compare evolutive changes of serum creatinine and urinary Gremlin. 
Spearman test was used to correlate urinary Gremlin and crescent percentage, serum creatinine, tisular Gremlin 
and TIF. Receiver operating characteristic (ROC) curves and Youden´s index were performed to determine the 
cut-off point, sensitivity and specificity of urinary Gremlin in renal pathology and pauci-immune crescentic 
GN. Area under the curve (AUC) was used to assess the diagnostic value and was reported with 95% CIs. p val-
ues < 0.05 were considered statistically significant.
Compliance with ethical standards. The samples were studied after informing and obtaining the patient 
written consent and the approval by local hospital ethics committee (Comité de Ética de Investigación, Servicio 
de Salud Valdivia, Ministerio de Salud, Chile). The study was in adherence with the Declaration of Helsinki.
Results
Urinary Gremlin levels are elevated in pauci-immune crescentic glomerulonephritis. Urinary 
Gremlin levels adjusted and not adjusted by urine creatinine, were significantly higher in patients with ANCA-
crescentic glomerulonephritis than in patients with other glomerular diseases (p < 0.0001) (Fig. 2A,B).
In order to define if these increased Gremlin values were only related to the presence of glomerular cres-
cents, we compared the values in ANCA-crescentic glomerulonephritis with other glomerulopthies (IgA and 
SLE nephropathy) that presented crescents in more that 25% of the glomeruli. Urinary Gremlin levels were 
Figure 1. Increase of serum creatinine (mg/dl) before renal biopsy in patients with ANCA+ Crescentic 
Glomerulonephritis. (A) 17 patients had a baseline mean serum creatinine (SCr) (mg/dl), of 1.50 ± 0.8, 
evaluated at different time points (one to 9 months) prior to the kidney biopsy. (B) At the time of the biopsy, the 
mean serum creatinine was 4,7 ± 2.6, with a median of 4.4 (IQR 4.8) (Wilcoxon p = 0.001).
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significantly higher in ANCA CGN (n = 20, 354 ± 76 ug/gCr) than those found in non-ANCA CGN in SLE 
(n = 17) and in IgA nephropathy (n = 3) that were 95.1 ± 15.2 ug/gCr). The urinary levels of Gremlin were very 
much lower in other non-crescentic renal diseases (Non CGN n = 66, 72.3 ± 6.8 ug/gCr) and healthy donors 
(11.3 ± 2.4 ug/gCr) (p < 0.0001) (Fig. 2C).
These values were correlated with tisular Gremlin protein measured by immunohistochemistry (IHC) in renal 
biopsy (p = 0.013 r = 0.64) (Fig. 2D). Next, we evaluated the relation between urinary Gremlin and different mark-
ers of renal damage in patients with ANCA vasculitis. and found there is a strong correlation between urinary 
Gremlin (ug/gCr) and serum creatinine (mg/dL) (p < 0.001, r = 0.60) (Fig. 3A), tubulointerstitial fibrosis evaluated 
by Masson staining (% staining area) (p < 0.05, r = 0.50) (Fig. 3B), number of crescents (%) (p < 0.001, r = 0.53) 
(Fig. 3C) and presence of macrophages CD68 positive cells (area mm2/Dens) (p < 0.005, r = 0.71) (Fig. 3D).
Finally, in order to reject the hypothesis that the difference in urinary Gremlin was only attributed to the num-
ber of crescents, we compared patients from both groups, vasculitic and non vasculitic glomerular diseases (15 
each group) with a similar number of crescents, observing a strongest amount of urinary Gremlin only in ANCA 
positive patients (358 ug/gCr vs 102 ug/gCr) (Table 3).
Receiver-operating characteristic (ROC) analysis. In the ROC curves generated to predict accuracy 
of urinary Gremlin to be a non-invasive biomarker for patients with renal pathology, we reported a cutoff value 
of 17 ug/gCr of urinary Gremlin for healthy controls and 43 ug/gCr as a cutoff value for patients with glomerular 
diseases (n = 106) with 72% of sensitivity and 100% of specificity; AUC: 0.96 (CI 95% 0.92–0.99) (Fig. 4A). Also, 
in a similar manner, in patients with glomerular diseases with crescents (ANCA vasculitis and non-vasculitis) 
(n = 40) we reported a cutoff value of 72.2 ug/gCr with 72.5% of sensitivity and 72% of specificity, AUC: 0.78 
(CI 95% 0.69–087) (Fig. 4B), and finally in patients with ANCA Vasculitis (n = 20) we reported a cutoff value of 
241.3 ug/gCr of urinary Gremlin with 55% of sensitivity and 100% of specificity. AUC: 0.81 (CI 95% 0.68–0.94) 
(p < 0.001) (Fig. 4C). These curves predict the ability of urinary Gremlin to be a non-invasive biomarker for 
patients with this renal pathology.
Figure 2. Evaluation of urinary Gremlin in glomerular diseases. (median and interquartile range). (A) Urinary 
Gremlin adjusted by urinary creatinine (ugGr/grCr) was significantly higher in patients with ANCA − CGN 
versus patients with other glomerular diseases (p < 0.0001). (Mdn = 274, IQR = 375 ug/grCr). (B) Unadjusted 
Urinary Gremlin observed confirming a significant higher median values for ANCA vasculitic patients. 
(Mdn = 159,5, IQR = 190) (C) Gremlin levels were still markedly and significantly higher in ANCA + CGN 
(n = 20) (Mdn = 274, IQR 375) compared with non-vasculitic GN with crescents (n = 17 SLE, 3 IgAN) 
(Mdn = 75, IQR 106) and other glomerular diseases without crescents (non CGN n = 66) (Mdn = 56, IQR 59 
ug) and healthy donors (Mdn 9.35, IQR 7.7 ug/gCr) (p < 0.0001). (D) Spearman correlation between Gremlin 
protein staining observed by immunohistochemistry (IHC) in renal biopsies and urinary Gremlin excretion 
expressed as ug/grCr (n = 12) (r = 0.64, p = 0.013).
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Follow up study of urinary Gremlin in patients with ANCA + CGN. All the patients received an induction ther-
apy with corticosteroids, cyclophosphamide or rituximab, by three or six months. Follow-up determinations of 
urinary Gremlin were carried out after induction therapy in a small cohort of patients, while in remission. As 
observed in Fig. 5, those patients with a particularly active disease at the beginning, showed a significant reduc-
tion of urinary Gremlin during remission. (499 ± SE 249 vs. 168 ± 75; median 292 vs. 93 ug/grCr; p < 0.001).
Renal Gremlin. Renal Gremlin protein expression was evaluated by immunohistochemistry in 35 
patients with glomerular diseases with crescents (ANCA+ vasculitis and non vasculitis). In 12 patients with 
pauci-immune crescentic glomerulonephritis, Gremlin was mainly detected in areas with cellular crescents, 
tubular cells and interstitial inflammatory cells (arrows) (Fig. 6A patients 1 and 2). Also, Gremlin staining was 
detected in crescents and tubular cells in IgA nephropathy and SLE Class IV GN, but with lower intensity than 
ANCA+ vasculitis (Fig. 6A patients 3 and 4). In these patients Gremlin mRNA was confirmed by ISH in crescen-
tic proliferative cells, tubular epithelial cells, and interstitial inflammatory cells. In serial sections of a representa-
tive case of ANCA+ vasculitis (12 patients studied) a clear co-localization between Gremlin protein and mRNA 
was observed (Fig. 6B). As noted, tisular Gremlin was significantly correlated with urinary Gremlin (Fig. 2D).
Figure 3. Spearman correlation of urinary Gremlin levels with indices of renal damage in patients with 
CGN. We evaluated the relation between urinary Gremlin and different markers of renal damage. There 
was a significant correlation between urinary Gremlin and (A) Serum creatinine (p < 0.001 r = 0.60). (B) 
Tubulointerstitial fibrosis evaluated by Masson staining (p < 0.05 r = 0.50). (C) Percentage of glomerular 
crescents (%) (r = 0.53, p < 0.001) and (D) Presence of macrophages (CD68 positive cells) (Area mm2/Dens) 
(r = 0.71, p < 0.005) observed in kidney biopsies of patients with CGN.
ANCA-CGN (n = 15) SLE-CGN (n = 15)
Urinary Gremlin 
(ug/gCr) % crescents
Urinary Gremlin 
(ug/gCr) % crescents
Mean 358 43 102 34
e.s.m 93 3.2 25 4.9
median 292 40 86 30
Table 3. Urinary Gremlin was significantly increased in crescentic ANCA vasculitis versus crescentic non 
vasculitic.
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Gremlin and Inflammation markers. Monocytes/macrophages play an important role in active glo-
merular inflammation and may be detected by different phenotypic markers20. Tissue macrophages are divided 
into the M1 and M2 subtypes according to the expression of different surface molecules and transcription fac-
tors. As it has been proposed that macrophages can directly transdifferentiate into myofibroblasts through a 
macrophage-myofibroblast transdifferentiation process21, we evaluated macrophage infiltration by identifying 
CD68+ cells (specific pan-monocyte/macrophage marker) as well as CD163+ cells, a marker that is increased in 
M2 macrophages22.
In addition, macrophages and dendritic cells in the kidney were identified as CCL-18 producing cells, that 
are known to drive renal inflammation in ANCA-associated crescentic GN23. Previously, we have shown that 
Gremlin expression is also induced in human monocytic cells stimulated in vitro by TGF-β19.
In the present study, in patients with ANCA + CGN we observed a strong expression of Gremlin protein in 
cellular crescents and interstitial inflammatory cells that showed co-expression of CD163, CCL-18 and CD68 
(Fig. 6C).
Figure 4. Receiver-operating characteristic (ROC) analysis of urinary Gremlin in patients with different 
glomerular diseases. In ROC curves we reported (A) cutoff value of 43 ug/gCr for patients with glomerular 
diseases with 72% of sensitivity and 100% of specificity. AUC: 0.96 (95% CI 0.92–0.99) (p < 0.001). (B) In 
patients with glomerular diseases with crescents, we reported a cutoff value of 72.2 ug/gCr of urinary Gremlin 
with 72.5% of sensitivity and 72% of specificity. AUC 0.78 (95% CI 0.69–0.87) (p < 0.001). (C) In patients with 
ANCA Vasculitis we reported a cutoff value of 241.3 ug/gCr with 55% of sensitivity and 100% specify. AUC: 
0.81 (CI 95% 0.68–0.94) (p < 0.001).
Figure 5. Follow up study of urinary Gremlin in patients with ANCA + CGN. In 5 patients, while in remission, 
post induction therapy, there was a significant decreased of Urinary Gremlin levels, (ug/gCr), mainly observed 
in those patients with severe histologic activity. (Mean ± SEM = 499 ± 249 versus 168 ± 75; Mdn 292 versus 93; 
Wilcoxon p < 0.001).
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Discussion
In this prospective study we have demonstrated for the first time that Gremlin may represent a new biomarker of 
ANCA-associated renal vasculitis which can be linked directly to the underlying pathophysiology of this glomer-
ular disease. High urinary levels of Gremlin are associated with a more severe disease activity as represented by 
the number of glomerular crescents, tubulointerstitial fibrosis and interstitial inflammation. Furthermore, in this 
study we observed a close correlation between kidney and urinary Gremlin and a significant positive correlation 
between the serum creatinine and urinary Gremlin, at the beginning and in the follow up study of these patients.
Although our observation was made in a relative modest number of patients with ANCA+ crescentic GN, 
the ELISA employed and range of urinary Gremlin values in our study are in agreement with those reported by 
Afkarian et al.24, in a group of patients with diabetic nephropathy.
ANCA-associated vasculitis is the major cause of rapidly progressive GN, and despite advances in our 
understanding of the pathogenesis of the disease, renal outcomes remain poor in a considerable percentage of 
patients25. The cellular crescent formation results from disruption of glomerular capillaries that allows inflamma-
tory mediators and infiltrating cells to enter Bowman´s space, where they induce activation and proliferation of 
parietal epithelial cells (PECs), monocytes/macrophages and fibroblasts infiltration26. Previously, we have already 
reported strong expression of Gremlin mRNA and protein in cellular and fibrocellular crescents, particularly in 
proliferating parietal epithelial cells and monocytes, suggesting a pathogenic role of Gremlin in crescents for-
mation19. It is important to note, that with a comparable percentage of mainly fibrocellular glomerular crescents 
(43 ± 3 versus 34 ± 5), patients with pauci immune disease had markedly higher urinary levels of Gremlin than 
patients with lupus nephritis or IgA nephropathy (298 ug/gCr versus 86 ug/gCr).
The role of Gremlin as a BMP antagonist has clearly been demonstrated in fibrotic related disorders, either 
acting as an inhibitory trap protein for BMP-7 or directly as a downstream mediator of TGF-β1,7. Experimental 
studies have shown that Gremlin contributes to renal fibrosis, as confirmed in vitro by its role in the regulation 
of fibroblasts proliferation and matrix production and in the induction of epithelial to mesenchymal transition 
of tubular epithelial cells1. More recently, we have demonstrated that Gremlin is a ligand of vascular endothe-
lial growth factor receptor 2 in tubular epithelial cells, and participates in the regulation of renal inflammation 
by activation of the Nuclear Factor-KB pathway and chemoattraction for monocytes/macrophages through 
induction of MCP-19. These considerations led us to speculate that urinary Gremlin shed by crescent mac-
rophages could correlate with active glomerular inflammation and participate in the interstitial inflammatory 
response.
Figure 6. Localization of Gremlin and inflammatory markers in crescentic glomerulonephritis. (A) In renal 
biopsies from patients with ANCA associated CGN (case 1 and 2), Gremlin protein was detected at glomeruli 
in cellular crescents, at tubular cells, and interstitial infiltrating cells, mainly monocytes-macrophages (arrows). 
In patients with IgA (case 3) and Lupus Nephritis (case 4), Gremlin protein was mainly detected in cellular 
crescents and tubular cells. (B) By in situ hybridization, Gremlin mRNA was mainly detected in glomerular 
podocytes and parietal epithelial cells, and interstitial tubular cells. In serial sections of a representative 
case of ANCA + CGN a clear co-localization between Gremlin protein and mRNA was found in all renal 
structures. Gremlin protein and mRNA is not observed in Normal Kidney. (C) There was a clear co-localization 
between Gremlin protein staining and CD68, CD163 and CCL18 as activate monocyte/macrophages 
markers respectively. Immunohistochemistry was done in serial sections of renal biopsy from patients with 
ANCA + CGN. Figure C shows a representative case of at least 10 studied. Magnification 200x and 400x, as 
indicated.
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Infiltrating macrophages are found in all renal diseases. The role of macrophages in the progression of renal 
damage is attracting special interest. Although M1 macrophages are more pro inflammatory and M2 macrophages 
have been suggested to exert anti-inflammatory and tissue repair properties, important questions regarding role 
of M1/M2 in acute phase and in the transition to fibrosis or recovery are still unresolved. Previous studies have 
observed that M2 macrophages are involved in the pathogenesis of acute tubulointerstitial lesions in patients with 
crescentic glomerulonephritis22, and other acute renal diseases, as recently observed in Sjogren’s disease, were 
CD163-positive macrophages are positively correlated with urinary NAG and β2-microglobulin27.
We have observed that in patients with ANCA + CGN the expression of Gremlin is localized in CD68, CD163 
and CCL-18 positive cells, supporting the important role of macrophages, including M2 macrophages, in the 
pathogenesis of ANCA-associated crescentic GN. Previous studies have shown that urinary excretion of soluble 
CD163 (sCD163) is a biomarker of macrophage activation in rats with experimental vasculitis and in patients 
with small vessel vasculitis and lupus nephritis20,28. Urinary sCD163 levels are elevated in active renal vasculitis, 
compared with patients with active extrarenal vasculitis and all patients in remission20. We require further studies 
to validate Urinary Gremlin, as a comparable biomarker in those clinical conditions.
The CC chemokine ligand 18 (CCL18), acting through CC chemokine receptor 8 (CCR8) on mononuclear 
cells, was identified as the most upregulated chemotactic cytokine in patients with ANCA-associated vasculi-
tis and correlated with crescent formation, interstitial inflammation, and impairment of renal function. Serum 
CCL18 levels were higher in patients with renal ANCA disease compared with patients with other forms of 
crescentic GN23. The localization of Gremlin in CCL-18, CD163, and CD68 positive cells suggests a key role of 
activated macrophages on the crescent formation and in interstitial inflammation.
Limitations of our work include that selection and study of our patients are from a single center and the num-
ber of patients and the follow-up were limited. The modifications of urinary Gremlin by therapeutic interventions 
need to be confirmed in a larger number of patients, specially since only 2 out of 20 cases are pattern C-ANCA 
(PR3 isotype). Therefore, additional studies are needed to confirm these results that potentially may be important 
in clinical practice.
In conclusion we have identified a highly specific association between ANCA+ crescentic glomerulonephritis 
and the level of urinary Gremlin. This protein is strongly expressed in glomerular crescents, as macrophages 
marker and the shedding of Gremlin directly into the urine makes it very attractive as a potential urinary bio-
marker of renal vasculitis.
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